Antimycobacterial potential of novel hydrazone derivatives

Molecular docking of 1 to 51 compounds has been performed in Small-Molecule Drug Discovery Suite of Schrödinger. Fifty one compounds have been targeted on 2NSD and 2X22 involved in tuberculosis activity. Aryloxy moiety on refluxing with chloroethyl acetate in the presence of potassium carbonate and acetone has yielded ethyl aryloxy acetate  (A), which have been reacted with hydrazine hydrate to produce aryloxyacetyl hydrazine  (B), which on treatment with aromatic aldehydes or ketones yield hydrazones  (C). The novel series of compounds have been elucidated on the basis of spectral studies and screened for antimycobacterial activity. The compounds are significantly sensitive at concentration 50 and 100 μg/mL. Compound 11 shows sensitivity at 25 μg/mL. The antibacterial activity is strongly connected with the position of the substituent on aromatic aldehyde or ketones in relation to the hydrazide skeleton

Antimycobacterial potential of novel hydrazone derivatives

700-709Molecular docking of 1 to 51 compounds has been performed in Small-Molecule Drug Discovery Suite of Schrödinger. Fifty one compounds have been targeted on 2NSD and 2X22 involved in tuberculosis activity. Aryloxy moiety on refluxing with chloroethyl acetate in the presence of potassium carbonate and acetone has yielded ethyl aryloxy acetate (A), which have been reacted with hydrazine hydrate to produce aryloxyacetyl hydrazine (B), which on treatment with aromatic aldehydes or ketones yield hydrazones (C). The novel series of compounds have been elucidated on the basis of spectral studies and screened for antimycobacterial activity. The compounds are significantly sensitive at concentration 50 and 100 μg/mL. Compound 11 shows sensitivity at 25 μg/mL. The antibacterial activity is strongly connected with the position of the substituent on aromatic aldehyde or ketones in relation to the hydrazide skeleton